Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
The metanalysis included 6 studies and 84 patients – from 5 observational and 1 randomized controlled trial. Efficacy of anakinra was suggested by:
- Subjective physician assessments with a positive clinical response rate of 76%
- Significant reduction of VAS scores by -48.12 mm (0-100 scale)
- Significant reduction in CRP levels by – 62.09 mg/L from baseline.
- Reduced TJC (-4.86) and SJC (-3.65)
Adverse reactions included injection site reaction, rash, bacterial pneumonitis, and neutropenia.
Anakinra appears to be effective in acute CPPD flares with a favourable safety profile.
Related Content
-
October 7, 2020A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can…
-
April 5, 2018The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6…
-
January 17, 2018Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile…
-
March 13, 2019
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly…
-
November 8, 2022 -
March 12, 2020An Italian study examined the outcomes in adult onset Still's disease (AOSD) based…